NASDAQ:MEIP MEI Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.59 +0.05 (+9.32%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$0.54▼$0.6050-Day Range$0.42▼$0.6552-Week Range$0.41▼$3.55Volume2.43 million shsAverage Volume5.02 million shsMarket Capitalization$77.99 millionP/E RatioN/ADividend YieldN/APrice Target$5.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MEI Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside774.0% Upside$5.13 Price TargetShort InterestHealthy15.50% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.86Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.69) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.08 out of 5 starsMedical Sector283rd out of 1,433 stocksPharmaceutical Preparations Industry125th out of 683 stocks 3.3 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.13, MEI Pharma has a forecasted upside of 774.0% from its current price of $0.59.Amount of Analyst CoverageMEI Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted15.50% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 71.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.93. Previous Next 2.1 News and Social Media Coverage News SentimentMEI Pharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MEI Pharma this week, compared to 1 article on an average week.Search InterestOnly 16 people have searched for MEIP on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.67% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions60.18% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($0.69) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About MEI Pharma (NASDAQ:MEIP) StockMEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Stock News HeadlinesJuly 6, 2022 | americanbankingnews.comMEI Pharma, Inc. (NASDAQ:MEIP) Receives $5.13 Average PT from BrokeragesJuly 3, 2022 | morningstar.comMEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | MorningstarJuly 7, 2022 | Weekly Investor Alerts (Ad)A Bigger Opportunity For Growth…A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks. June 25, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP)June 22, 2022 | finance.yahoo.comMEI Pharma Appoints Human Resources Executive Anne Frese as Chief People OfficerMay 23, 2022 | finance.yahoo.comMEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational HighlightsMay 23, 2022 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue EstimatesMay 18, 2022 | apnews.comINVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the FirmJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. May 17, 2022 | finance.yahoo.comMEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022May 17, 2022 | apnews.comINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the FirmMay 17, 2022 | apnews.comThe Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of InvestorsMay 12, 2022 | finance.yahoo.comWe're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn RateMay 12, 2022 | finance.yahoo.comMEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid CongressMay 4, 2022 | finance.yahoo.comPacira (PCRX) Q1 Earnings Miss EstimatesApril 8, 2022 | finance.yahoo.comMEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022March 28, 2022 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For MEI Pharma, Inc. (NASDAQ:MEIP)March 28, 2022 | msn.comAnalyzing Mei Pharma Inc's Short InterestMarch 25, 2022 | investing.com"Near-Term Zandelisib Launch off the Table" After "Bewildering" FDA Feedback – MEI Pharma (MEIP) Stock Crashes as Analysts Downgrades Roll InMarch 25, 2022 | markets.businessinsider.comExpert Ratings For MEI PharmaMarch 25, 2022 | finance.yahoo.comAnalysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib UpdateMarch 25, 2022 | seekingalpha.comMEI Pharma falls on setback to U.S. marketing application for lymphoma therapyMarch 24, 2022 | msn.comWhy MEI Pharma Stock Is Plummeting After HoursMarch 24, 2022 | finance.yahoo.comMEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDAMarch 8, 2022 | finance.yahoo.comMEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022February 12, 2022 | finance.yahoo.comAnalyst Forecasts Just Became More Bearish On MEI Pharma, Inc. (NASDAQ:MEIP)February 10, 2022 | finance.yahoo.comMEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational HighlightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees76Year FoundedN/ACompany Calendar Last Earnings5/23/2022Today7/07/2022Next Earnings (Estimated)9/01/2022Fiscal Year End6/30/2023Price Target and Rating Average Stock Price Forecast$5.13 High Stock Price Forecast$20.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+774.0%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,310,000.00 Net Margins-62.40% Pretax Margin-90.94% Return on Equity-71.32% Return on Assets-21.26% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.66 Sales & Book Value Annual Sales$25.53 million Price / Sales3.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book1.33Miscellaneous Outstanding Shares132,990,000Free Float125,446,000Market Cap$77.99 million OptionableOptionable Beta1.02 MEI Pharma Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock. View analyst ratings for MEI Pharma or view top-rated stocks. What is MEI Pharma's stock price forecast for 2022? 6 brokerages have issued twelve-month price targets for MEI Pharma's shares. Their MEIP stock forecasts range from $1.00 to $20.00. On average, they expect MEI Pharma's stock price to reach $5.13 in the next year. This suggests a possible upside of 774.0% from the stock's current price. View analysts' price targets for MEI Pharma or view top-rated stocks among Wall Street analysts. How has MEI Pharma's stock performed in 2022? MEI Pharma's stock was trading at $2.67 on January 1st, 2022. Since then, MEIP shares have decreased by 78.0% and is now trading at $0.5864. View the best growth stocks for 2022 here. When is MEI Pharma's next earnings date? MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, September 1st 2022. View our earnings forecast for MEI Pharma. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) posted its quarterly earnings results on Monday, May, 23rd. The company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The firm had revenue of $9.69 million for the quarter, compared to analysts' expectations of $6.25 million. MEI Pharma had a negative net margin of 62.40% and a negative trailing twelve-month return on equity of 71.32%. View MEI Pharma's earnings history. Who are MEI Pharma's key executives? MEI Pharma's management team includes the following people: Dr. Daniel P. Gold, Pres, CEO & Director (Age 68, Pay $1.03M)Mr. David M. Urso B.A., Esq., J.D., COO & Gen. Counsel (Age 58, Pay $680.47k)Dr. Robert D. Mass, Strategic Advisor (Age 68, Pay $201.68k)Dr. Richard G. Ghalie, Chief Medical Officer (Age 64, Pay $550.55k)Ms. Virginia Sankey, VP of Fin.Dr. Eric Deng Ph.D., VP of Technical OperationsMs. Tina Clark Beamon Esq., J.D., Chief Compliance OfficerMr. Brian T. Powl, Sr. VP of MarketingMs. Anne Frese, Chief People OfficerDr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 59) Who are some of MEI Pharma's key competitors? Some companies that are related to MEI Pharma include Biotech Acquisition (BIOT), CytoDyn (CYDY), Aadi Bioscience (AADI), Alpine Immune Sciences (ALPN), LianBio (LIAN), Verona Pharma (VRNA), Alaunos Therapeutics (TCRT), G1 Therapeutics (GTHX), Provention Bio (PRVB), CymaBay Therapeutics (CBAY), Rallybio (RLYB), PepGen (PEPG), Thorne HealthTech (THRN), InterCure (INCR) and Inventiva (IVA). View all of MEIP's competitors. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). What is MEI Pharma's stock symbol? MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP." How do I buy shares of MEI Pharma? Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MEI Pharma's stock price today? One share of MEIP stock can currently be purchased for approximately $0.59. How much money does MEI Pharma make? MEI Pharma (NASDAQ:MEIP) has a market capitalization of $77.99 million and generates $25.53 million in revenue each year. The company earns $-41,310,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. How many employees does MEI Pharma have? MEI Pharma employs 76 workers across the globe. How can I contact MEI Pharma? MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for MEI Pharma is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049. This page (NASDAQ:MEIP) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
